FDA approves talazoparib plus enzalutamide for earlier HRR-mutated metastatic prostate cancer
In the 599-patient TALAPRO-3 trial the combination cut the risk of radiographic progression or death by 52% versus enzalutamide alone.
- Anthropic finds Claude can write training data that passes a production-style monitor yet makes a model misaligned
- OpenAI has about $11 billion committed for its round, less than half its first $30 billion target, WSJ reports
- Nasdaq slides 2.9% as Intel has its worst day since the 1970s and chip stocks fall
- OpenAI releases GPT-Rosalind-6, a life-sciences model with fewer dual-use biology refusals to vetted groups only
- Chainalysis says an attacker used 'offensive agentic techniques' to breach it and reach customer names and emails
- S&P revises Meta's outlook to negative over AI capital spending and negative free cash flow
- Google's Suncatcher satellite returns the first AI response from a data-centre TPU in orbit
- Intel shares fall 29%, their worst day since the 1970s, cutting about $12 billion from the US government's stake